Navigation Links
Abbott's Absolute Pro® Vascular Self-Expanding Stent System Receives FDA Approval for Treatment of Iliac Artery Disease
Date:3/7/2012

ABBOTT PARK, Ill., March 7, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) approved the Absolute Pro® Vascular Self-Expanding Stent System for the treatment of iliac artery disease, a form of peripheral artery disease (PAD) that affects the lower extremities. Over time, iliac artery disease can progress to where patients have reduced walking ability, experience chronic pain and suffer permanent disability. This approval is supported by the MOBILITY (Omnilink Elite® or Absolute Pro Stent Used in the Iliac Artery) study, which demonstrated that Absolute Pro is safe and effective, even in patients with complex disease.

"Iliac artery disease greatly impacts patients' overall quality of life," said Tony S. Das, M.D., FACC, director, Peripheral Vascular Interventions, Cardiology Section, Presbyterian Heart Institute in Dallas, Texas, and co-principal investigator of the MOBILITY trial. "The goal of treatment is to open narrowed iliac arteries to restore blood flow to the legs, thereby alleviating pain and improving the patient's ability to walk farther and enjoy a more active lifestyle. With Absolute Pro, U.S. physicians now have an additional option that is proven safe and effective to treat many patients with this debilitating disease."

Absolute Pro is a self-expanding nitinol stent system made of a flexible material designed to allow the stent to conform to challenging lesions. It incorporates advanced technologies for optimal stent visibility, with a delivery system that is designed to minimize friction during stent deployment and ensure precise stent placement at the lesion site.

The FDA approval was supported by the results of the Absolute Pro arm of the MOBILITY trial, a prospective, non-randomized, two-arm, multi-center study that evaluated two Abbott stents, Absolute Pro and Omnili
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients
2. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
3. Leading Cardiovascular Organizations Release Credentialing Recommendations for Heart Valve Replacement Procedure
4. MarketsandMarkets: Global Peripheral Vascular & Interventional Cardiology Devices Market worth $37.9 Billion by 2016
5. U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
6. AccessClosure, Inc. Launches MynxGrip™ Vascular Closure Device
7. Terumo Cardiovascular Systems Becomes Exclusive U.S. Distributor for TigerPaw® System II, Left Atrial Appendage Closure Device
8. BridgePoint Medical Announces Licensing Agreement for its Peripheral Vascular Products
9. Journal of Cardiovascular Electrophysiology Study Shows Promising Single Ablation Procedure Outcomes With HeartLight EAS for Treatment of Atrial Fibrillation
10. FDA Expands Use of Endovascular Graft to Treat Aortic Tears
11. Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
(Date:1/22/2015)... 22, 2015  ViewRay™, a privately held medical device company, ... distributor agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: ... the treatment of cancer in Japan ... world,s first and only MRI-guided radiation therapy system that ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... (Nasdaq: THOR ), a world leader in device-based ... hearts, today announced that it will report its operating results ... 1. The company will hold a conference call ... all interested parties, at 1:30 p.m., Pacific Daylight Time (4:30 ...
... 2011 At the 5 ... in Barcelona, Spain (20-22 October 2011),   Merz Pharmaceuticals ... efficacy and safety of   XEOMIN ® ... Dystonia is a particularly debilitating condition ...
Cached Medicine Technology:Thoratec Schedules Third Quarter Conference Call, Webcast 2Merz research Shows Long-term Benefits for Patients With Dystonia 2Merz research Shows Long-term Benefits for Patients With Dystonia 3Merz research Shows Long-term Benefits for Patients With Dystonia 4
(Date:1/22/2015)... 2015 The U.S. Pharmacopeial Convention is ... of Clinical Pharmacy Services at North Carolina State’s College ... the 2015 Beal Award for Distinguished Volunteer Service—the organization’s ... on the contributions of volunteer experts to direct its ...
(Date:1/22/2015)... Nashville, TN (PRWEB) January 22, 2015 Gabe’s Chemo ... Chemo Duck App, the first app ever created for kids with ... all Apple phones and devices, is filled with enjoyable games to ... life and treatments. The free app helps to keep kids entertained, ...
(Date:1/22/2015)... Minn. (PRWEB) January 22, 2015 Blue Cross ... those Minnesotans who exemplify what it means to “Live Fearless.” ... chance for people to share their stories about how they ... or simply inspired others by living in the moment. By ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... disease requiring creative solutions for diagnosis, quality of life ... San Antonio Breast Cancer Symposium explore these areas. ... Cancer , Abstract #65, Sarah Marshall, M.A. , Although ... breast cancer, they appear to mitigate the mortality risk ...
... PartsSource, the nation,s leading,supplier of replacement medical repair parts for ... in Ohio by the Case Western Reserve,University Weatherhead ... placed 14th on this year,s list with a growth rate ... eligible. , "The Weatherhead ...
... WASHINGTON, Dec. 12 [The Washington Post ... and Drug Administration and the White House are considering easing ... certain fish. Scientists at the Environmental Protection Agency reportedly ... The move is one of several "midnight" rules and policy ...
... treatment decisions, study shows , , FRIDAY, Dec. 12 ... the risk of their breast cancer returning after ... get chemotherapy more difficult, a new study concludes. ... bar chart, based on a standard risk-assessment tool, ...
... Care Policy and Legislative Background Assures Strong Leadership for ... , WASHINGTON, Dec. 12 ... nation,s largest cancer treatment and research networks representing approximately ... of former Senator Tom Daschle to lead his newly ...
... report from the Institute of Medicine, THE U.S. COMMITMENT ... why a commitment to global health is an important ... the current economic situation. The report describes areas ... incoming administration should strive to meet, and makes specific ...
Cached Medicine News:Health News:Patient management: Quality of life and beyond 2Health News:Risk Info for Breast Cancer Patients Too Confusing 2Health News:US Oncology Applauds Senator Daschle's Appointment as Director of President-Elect Obama's New White House Office of Health Reform 2
Ergonomically designed, the Invacare Printing Pulse Oximeter provides fast, reliable spot-check information and documentation of SpO2 and pulse rate. It is ideal for all patients from neonate to adul...
The reliable and easy-to-use 3800 pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
... 8600 Series Tabletop/Portable Digital Pulse ... tool for patient monitering. From ... the 8600 has earned the ... and is recognized for its ...
... Resolve Immersion Oil is a clear, ... throughout most of the UV-VIS spectrum. ... and high viscosity, is non-drying and ... of 1.5150. Resolve contains no PCBs, ...
Medicine Products: